Charge Variant Analysis Global Market Report 2026

The charge variant analysis market size has grown strongly in recent years. It will grow from $1.15 billion in 2025 to $1.27 billion in 2026 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to growing biopharmaceutical production, rising need for protein characterization, adoption of chromatography-based analysis, increasing regulatory requirements for quality control, technological advancements in electrophoresis methods.

The charge variant analysis market size is expected to see strong growth in the next few years. It will grow to $1.85 billion in 2030 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to rising demand for automated cva systems, growing adoption of ai-enabled data analysis, expansion of biologics and biosimilars market, increasing focus on real-time monitoring of protein variants, integration of high-throughput analytical platforms. Major trends in the forecast period include increasing adoption of capillary electrophoresis techniques, rising demand for high-throughput ion exchange chromatography, growing integration of cva software for data analysis, expansion of analytical services for biopharmaceutical qa/qc, rising focus on multi-product and platform development.

The expanding adoption of biosimilars is projected to drive the growth of the charge variant analysis market in the future. Biosimilars are biologic products highly similar to an already approved reference biologic in terms of safety, efficacy, and quality, though they may contain minor variations in clinically inactive components. The rising use of biosimilars is due to patent expirations on original biologic drugs, allowing manufacturers to produce lower-cost, clinically equivalent alternatives, which increases accessibility and market competition. Charge variant analysis supports biosimilars by verifying their structural and functional equivalence to the reference biologic, enabling accurate evaluation of product quality, stability, and therapeutic consistency. For example, in January 2023, according to Cardinal Health Inc., a US-based healthcare company, the number of FDA-approved biosimilar products in the U.S. rose from 33 in 2022, with 21 commercially available, to 40 in 2023, with 25 available on the market. Therefore, the growing use of biosimilars is driving the expansion of the charge variant analysis market.

Leading companies operating in the charge variant analysis market are increasingly focusing on developing innovative analytical solutions, such as advanced capillary isoelectric focusing-mass spectrometry (cIEF-MS) platforms, to enable faster, more precise, and high-resolution characterization of protein therapeutics. Capillary isoelectric focusing-mass spectrometry is an analytical technique that separates proteins based on their isoelectric point and subsequently identifies and characterizes charge variants using mass spectrometry, allowing detailed and accurate profiling of protein heterogeneity. For example, in June 2024, CMP Scientific Corp., a US-based biotechnology company, launched the BioSummit CVA System, an advanced cIEF-MS platform for online charge variant analysis. The system combines the company’s proprietary EMASS II CE-MS coupling technology with CR3520 cIEF-MS chemistry and a novel time-of-flight mass spectrometer to deliver high sensitivity, robustness, and seamless analytical workflows tailored for recombinant protein characterization. It enables high-resolution separation and identification of charge variants in a single integrated run, features streamlined reagent workflows, enhanced operational robustness, and comprehensive data analysis software, making it suitable for biopharmaceutical research, quality control, and regulatory support applications.

In February 2026, CMP Scientific Corp., a US-based analytical technology company offering advanced, high-resolution charge variant analysis (CVA) solutions, partnered with Eurofins BPT China Laboratory to provide enhanced CE MS services for biopharmaceutical characterization. This partnership aims to improve charge variant analysis and overall protein therapeutic characterization by combining CMP Scientific’s expertise in capillary electrophoresis-mass spectrometry (CE MS) workflows with Eurofins BPT China Laboratory’s global analytical service capabilities. Eurofins BioPharma Product Testing (Shanghai) Co Ltd. is a China-based contract research organization specializing in analytical testing and biopharmaceutical development services.

Major companies operating in the charge variant analysis market are Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, SGS Société Générale de Surveillance SA, Lonza Group AG, Agilent Technologies Inc., Creative Proteomics Inc., WuXi AppTec Co Ltd., Charles River Laboratories International Inc., Sartorius AG, Shimadzu Corporation, Waters Corporation, Revvity Inc., Bio-Rad Laboratories Inc., Phenomenex Inc., Tosoh Bioscience LLC, JASCO Inc., Alturas Analytics Inc., BioPharmaSpec Inc., Eurofins Scientific SE.

North America was the largest region in the charge variant analysis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the charge variant analysis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the charge variant analysis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The charge variant analysis market consists of revenues earned by entities by providing services such as protein charge profiling, capillary isoelectric focusing (CIEF) analysis, mass spectrometry-based characterization, method development and validation, and stability and comparability studies. The market value includes the value of related goods sold by the service provider or included within the service offering. The charge variant analysis market also includes sales of analytical instruments, consumables, technique specific platforms, workflow kits and method packages, hardware accessories, and chromatography consumables and accessories. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Charge variant analysis (CVA) is a method applied in biopharmaceutical development to detect and measure different charged forms of proteins or antibodies, which may result from post-translational modifications, degradation, or manufacturing processes. It ensures product consistency, stability, and effectiveness by tracking these charge variants throughout development and production.

The key techniques of charge variant analysis include ion exchange chromatography, capillary electrophoresis, isoelectric focusing, and others. Ion exchange chromatography is a separation method that isolates molecules based on their net electrical charge by using a charged stationary phase to attract oppositely charged ions. Product types include instruments, consumables, software, and services. Applications span biopharmaceuticals, research and development, quality control, and other areas, while end users include pharmaceutical and biotechnology companies, academic and research institutes, contract research organizations, and other end-users.

Tariffs on imported analytical instruments, chromatography columns, and mass spectrometry equipment are impacting the charge variant analysis market by increasing procurement and operational costs, particularly affecting instruments, consumables, and software segments. Regions such as North America, Europe, and Asia-Pacific, which rely heavily on imported laboratory equipment, are most affected. While tariffs elevate costs, they also encourage domestic manufacturing, local sourcing of consumables, and innovation in cost-efficient analytical platforms, providing opportunities for regional supply chain development and self-reliance.

The charge variant analysis market research report is one of a series of new reports that provides charge variant analysis market statistics, including charge variant analysis industry global market size, regional shares, competitors with a charge variant analysis market share, detailed charge variant analysis market segments, market trends and opportunities, and any further data you may need to thrive in the charge variant analysis industry. This charge variant analysis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.